Research Program: Women's Cancer
Assistant Professor, Department of Obstetrics, Gynecology and Women's Health

gelle005@umn.edu
612-626-3111—office

Dr. Geller's clinical profile
(University of Minnesota Physicians Web site)

Dr. Geller graduated cum laude with honors in Biology from Boston College. She received her M.D. degree from Chicago Medical School Finch University of Health Sciences and completed her residency in Obstetrics and Gynecology at the University of Minnesota. She conducted a fellowship in gynecologic oncology surgery at Memorial-Sloan Kettering Cancer Center followed by a fellowship in gynecologic oncology at the University of Minnesota. She joined the faculty in the Department of Obstetrics, Gynecology and Women's Health in 2005. Dr. Geller is board-certified in obstetrics and gynecology and in gynecologic oncology.

Research Interests

Dr. Geller's clinical interests are ovarian cancer and the treatment of uterine tumors. Her active research interests are as follows:

1. The use of allogeneic natural killer (NK) cells in the treatment of ovarian cancer
2. MCP-1 (Macrophage Chemotactic Protein-1) levels in patients with newly diagnosed ovarian cancer receiving chemotherapy
3. Women's Cancer Center Protocol # 38: A Phase II trial of induction carboplatin and docetaxel followed by radiotherapy then consolidation chemotherapy with carboplatin and docetaxel in Stage III, IV, and recurrent endometrial cancer
4. Alterations in Serotonin (5-HT) signaling as a mechanism for chemotherapy induced constipation in Ovarian Cancer Patients
5. Use of multimedia materials for educational materials for women with newly diagnosed ovarian cancer

Selected Publications

Downs LS Jr, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, Nahhas WA, Abu-Ghazaleh SZ, Chen MD, Carson LF. A prospective randomized trial of thalidomide with topotecan compared with topote2can alone in women with recurrent epithelial ovarian carcinoma. Cancer. 2008;112:331-339.

Zins AM, Thomas SG, Judson PL, Geller MA. Intussusception caused by metastatic cervical cancer. Int J Gynaecol Obstet. 2008;103:262-263.

Johnson JR, Lacey JV Jr, Lazovich D, Geller MA, Schairer C, Schatzkin A, Flood A. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:196-203.

Tan A, Argenta P, Ramirez R, Bliss R, Geller M. The use of sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier in gynecologic malignancies: A retrospective review of Detection. Ann Surg Oncol. 2009;16:499-505.

Geller MA, Argenta PA, Thomas SG, Dusenbery KE, Judson PL, Boente MP. Feasibility and morbidity of using saline filled tissue Expanders to reduce radiation-induced bowel injury in patients with gynecologic malignancies. Eur J Obstet Gynecol Reprod Biol. 2009;143:93-97.

Argenta PA, Thomas SG, Judson PL, Downs LS Jr, Geller MA, Carson LF, Jonson AL, Ghebre R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol. 2009;113:205-209.

Ivy JJ, Geller M, Pierson SM, Jonson AL, Argenta PA. Detection associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: A single institution's experience. Gynecol Oncol. 2009;114:420-423.

Geller MA, Ivy J, Dusenbery KE, Ghebre R, Isaksson Vogel R, Argenta PA. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the 'sandwich' method for high risk endometrial carcinoma. Gynecol Oncol. 2010;118:19-23.

Geller MA, Bui-Nguyen TM, Rogers LM, Ramakrishnan S. Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. Int J Gynecol Cancer. 2010;20:918-925.

Jonson AL, Geller MA, Dickson EL. Gonadal dysgenesis and gynecologic cancer. Obstet Gynecol. 2010;116(Suppl 2):550-552.

Anderson JD, Boylan KL, Jemmerson R, Geller MA, Misemer B, Harrington KM, Weivoda S, Witthuhn BA, Argenta P, Isakkson Vogel R, Skubitz AP. Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J Ovarian Res. 2010;3:21.

Geller MA, Downs LS, Judson PL, Ghebre R, Argenta PA, Carson LF, Jonson AL, Godfrey K, Vogel RI, Petzel SV. Learning about ovarian cancer at the time of diagnosis: Video versus usual care. Gynecol Oncol. 2010;119:370-375.

Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker.Am J Clin Pathol.  2010;134:835-845.

Geller MA, Cooley S, Argenta PA, Downs LS , Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother.  2010; 59:1877-1884.

Kothari R, Nagel C, Koopmeiners JS, Ivy JJ, Geller M, Salani R, Argenta PA. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. Gynecol Oncol. 2010;11:491-495.

Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. A phase II study of allogeneic natural killer cells therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98-107.

Downs LS Jr, Chura JC, Argenta PA, Judson PL, Ghebre R, Geller MA, Carson LF. Ifosfamide, paclitaxel, and carboplatin a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II Trial. Gynecol Oncol. 2011;120:265-269.

Geller MA, Ivy JJ, Ghebre R, Downs LS Jr., Judson PL, Carson LF, Jonson AL, Kathryn Dusenbery K, Isaksson Voge R, Boente MP, Argenta PA. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol, 2011;121:112-117.

Ghebre RG, Posthuma R, Vogel RI, Geller MA, Carson LF. Effect of age and comorbidity on the treatment and survival of older patients with vulvar cancer. Gynecol Oncol. 2011;121:595-599.